Author:
Jin Dian,Le Jing,Yang Qianqian,Cai Qianqian,Dai Hui,Luo Liufei,Tong Jiaqi,Shu Wenxiu
Abstract
Abstract
Background
Previous studies achieved low microbial detection rates in lymphoma patients with interstitial pneumonia (IP) after chemotherapy. However, the metagenomic next-generation sequencing (mNGS) is a comprehensive approach that is expected to improve the pathogen identification rate. Thus far, reports on the use of mNGS in lymphoma patients with chemotherapy-related IP remain scarce. In this study, we summarized the microbial detection outcomes of lymphoma patients with chemotherapy-related IP through mNGS testing of bronchoalveolar lavage fluid (BALF).
Methods
Fifteen lymphoma patients with chemotherapy-related IP were tested for traditional laboratory microbiology, along with the mNGS of BALF. Then, the results of mNGS and traditional laboratory microbiology were compared.
Results
Of the 15 enrolled patients, 11 received rituximab and 8 were administered doxorubicin hydrochloride liposome. The overall microbial yield was 93.3% (14/15) for mNGS versus 13.3% (2/15) for traditional culture methods (P ≤ 0.05). The most frequently detected pathogens were Pneumocystis jirovecii (12/15, 80%), Cytomegalovirus (4/15, 26.7%), and Epstein-Barr virus (3/15, 20%). Mixed infections were detected in 10 cases. Five patients recovered after the treatment with antibiotics alone without glucocorticoids.
Conclusion
Our findings obtained through mNGS testing of BALF suggested a high microbial detection rate in lymphoma patients with IP after chemotherapy. Notably, there was an especially high detection rate of Pneumocystis jirovecii. The application of mNGS in patients with chemotherapy-related IP was more sensitive.
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Infectious Diseases,Oncology,Epidemiology
Reference66 articles.
1. Armitage JO, Gascoyne RD, Lunning MA, Cavalli F. Non-hodgkin Lymphoma. Lancet. 2017;390(10091):298–310.
2. Liu WP, Wang XP, Zheng W, Xie Y, Tu MF, Lin NJ, et al. Incidence, clinical characteristics, and outcome of interstitial Pneumonia in patients with Lymphoma. Ann Hematol. 2018;97(1):133–9.
3. Salmasi G, Li M, Sivabalasundaram V, Panzarella T, Tsang R, Kukreti V, et al. Incidence of pneumonitis in patients with non-hodgkin Lymphoma receiving chemoimmunotherapy with rituximab. Leuk Lymphoma. 2015;56(6):1659–64.
4. Zhou T, Shen Q, Peng H, Chao T, Zhang L, Huang L, et al. Incidence of interstitial pneumonitis in non-hodgkin’s Lymphoma patients receiving immunochemotherapy with pegylated liposomal doxorubicin and rituximab. Ann Hematol. 2018;97(1):141–7.
5. Meng YN, Wang S, Shi Q, Xu PP, Cheng S, Wang L, et al. [Interstitial Pneumonia in patients with diffuse large B-cell Lymphoma receiving RCHOP and RCDOP regimens]. Zhonghua Xue Ye Xue Za Zhi. 2019;40(12):1015–20.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Multiple drugs;Reactions Weekly;2024-01-20